Populations for Analyses Clause Samples

The "Populations for Analyses" clause defines the specific groups of study participants whose data will be included in various statistical analyses during a clinical trial. Typically, this clause outlines criteria for different analysis populations, such as the intent-to-treat group (all randomized subjects), per-protocol group (those who completed the study as planned), or safety population (all subjects who received at least one dose of the investigational product). By clearly specifying which participants' data are analyzed for efficacy, safety, or other endpoints, this clause ensures consistency, transparency, and scientific validity in the interpretation of trial results.
Populations for Analyses. ‌‌ The analysis populations will consist of subjects as defined below: • The Screened Analysis Set includes all subjects who are screened for the study. This population is used primarily for subject accounting purposes and will generally not be used for summary or analysis. • The Randomized Set includes all subjects who are randomized to receive study drug regardless of whether they take a dose. • The Safety Analysis Set includes all subjects who receive at least one dose of study drug. Subjects will be classified according to the treatment they actually receive. • The Full Analysis Set (FAS) includes all randomized IBS-D and IBS-M subjects who took at least one dose of double-blind study drug and had a baseline diary assessment and at least 1 post -randomization diary entry. Subjects will be analyzed according to randomized treatment, irrespective of whether or not they have prematurely discontinued, according to the Intent -to-Treat principle. The Full Analysis Set for IBS-D (FAS-D) and Full Analysis Set for IBS-M (FAS-M) are each a subset of FAS and consists of IBS-D and IBS-M subjects, respectively. The FAS-D will serve as the primary population for the primary analysis of efficacy data in this study. • The Per-Protocol Set for IBS-D excludes subjects from the FAS-D due to important deviations from the protocol that may substantially affect the result of the primary efficacy endpoint (ie, Major Protocol Deviations associated with efficacy). The Per -Protocol Set will serve as the supportive population for the analysis of efficacy data in this study. Other Per- Protocol Sets may be defined.
View Source
Populations for Analyses. ‌ The following study populations are defined and will be analyzed as specified below. All evaluable patients fit into the Safety dataset, among other datasets: The Intent to Treat (ITT) dataset: the total population of patients registered in the study. Safety dataset: all registered participants who received at least one Chemoplaque study intervention. Efficacy population: all enrolled patients who completed 42 days with at least one Chemoplaque and had adequate assessment of disease progression. Any patient who is registered on to this trial but never receives study treatment will be described, including the reason(s) for non-participation. All patients that receive a study dose will be included in all analyses. Any patient who is registered but never receives study treatment will be described, including the reason(s) for non-participation.
View Source
Populations for Analyses. ‌ All patients who receive at least 1 dose of ALXN2050 will be included in the safety and efficacy analyses.
View Source
Populations for Analyses. The population sets used for analysis sets are defined in Table 6.
View Source
Populations for Analyses. The following analysis populations are planned: Full Analysis Set All subjects who are randomized. Subjects will be classified according to the treatment assigned at randomization. The Full Analysis Set will be the primary population for evaluating all efficacy endpoints and subject characteristics. Per-protocol Analysis Set A subset of the Full Analysis Set and will include subjects who receive at least 1 dose of study treatment and do not have major protocol deviations expected to impact the primary objective of the study. Major protocol deviations will be pre-specified in the SAP. The Per-protocol Analysis Set will be used for sensitivity analyses for the primary efficacy endpoint. Safety Analysis Set All subjects who receive at least 1 dose of study treatment. Subjects will be classified according to the treatment assigned at randomization unless the incorrect treatment(s) are received throughout the dosing period, in which case subjects will be classified according to the first treatment received. The Safety Analysis Set will be the primary population for evaluating treatment administration/compliance and safety. PK Analysis Set All treated subjects who have at least 1 concentration above the limit of quantitation of the study treatment in RIST4721 arm only.
View Source

Related to Populations for Analyses

  • Technology Research Analyst Job# 1810 General Characteristics

  • Quantitative Analysis Quantitative analysts develop and apply financial models designed to enable equity portfolio managers and fundamental analysts to screen potential and current investments, assess relative risk and enhance performance relative to benchmarks and peers. To the extent that such services are to be provided with respect to any Account which is a registered investment company, Categories 3, 4 and 5 above shall be treated as “investment advisory services” for purposes of Section 5(b) of the Agreement.”

  • Maps The maps service and features of the Apple Software (“Maps”), including map data coverage, may vary by region. When you turn on or use Maps, details will be provided regarding what information is sent to Apple and how the information may be used. You acknowledge and agree that your use of Maps is subject to the latest terms and conditions of the Maps service, which you may access and review on the Maps home card.

  • Special Analyses It is hereby certified that these regulations will not have a significant economic impact on a substantial number of small entities. This certification is based on the fact that it is unlikely that a substantial number of small entities will hold REMIC residual interests. Therefore, a Regulatory Flexibility Analysis under the Regulatory Flexibility Act (5 U.S.C. chapter 6) is not required. It has been determined that this Treasury decision is not a significant regulatory action as defined in Executive Order 12866. Therefore, a regulatory assessment is not required. It also has been determined that sections 553(b) and 553(d) of the Administrative Procedure Act (5 U.S.C. chapter 5) do not apply to these regulations. The principal author of these regulations is ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇. However, other personnel from the IRS and Treasury Department participated in their development. 26 CFR Part 1 Income taxes, Reporting and record keeping requirements.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.